Niedlfree Technologies

Niedlfree Technologies is an Indian biotechnology company specializing in the development of needle-free, oral and nasal spray formulations of complex biologics and peptides. Formed as an associate company of Transgene Biotek, Niedlfree utilizes a proprietary functionalized nano-particle technology platform to encapsulate large molecules, protecting them from enzymatic degradation and enhancing their bioavailability. The company's lead program is Ozulin, an oral insulin spray for type 1 and type 2 diabetes that has demonstrated over 91% bioavailability in canine studies. Niedlfree is also advancing a pipeline of oral and nasal formulations for other therapeutic areas, including GLP-1 agonists (semaglutide and liraglutide) for obesity and diabetes, teriparatide for osteoporosis, and early-stage gene therapies.